Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02918929 · ClinicalTrials.gov registry record · Phase 1

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

A Phase 1 study, sponsored by Enanta Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
146
Enrollment target

NCT02918929: Completed Phase 1 study, sponsored by Enanta Pharmaceuticals.

NCT02918929 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 146 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (143% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02918929, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
146 participants
Enrollment target

Study Summary

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-305 in healthy adult subjects, and adult subjects with presumptive NAFLD (i.e., obese subjects with or without prediabetes or T2DM).

Interventions

  • DRUG Placebo
  • DRUG EDP 305

Trial Details

FieldValue
Enrollment Target 146 participants
Start Date 2016-09
Est. Completion 2017-06
Phase Phase 1
Enanta Pharmaceuticals

36 total trials

What the finished NCT02918929 record still lists

NCT02918929 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (143% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02918929 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02918929 about?

NCT02918929 is a clinical study titled "A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD". This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-305 in healthy adult subjects, and adult subjects with presumptive NAFLD (i.e., obese subjects with or without prediabetes or T2D...

What is the current status of trial NCT02918929?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 146 participants. The study started on 2016-09. Estimated completion is 2017-06.

What interventions are being tested in trial NCT02918929?

The interventions under investigation include: Placebo (DRUG), EDP 305 (DRUG).

Who is sponsoring clinical trial NCT02918929?

This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02918929's enrollment target sits among peer trials

146 391st of 2000 higher than 1,610 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03490929 · 146 participants · Phase 4

    CEUS for Blunt Abdominal Trauma in Children

  • NCT04755062 · 146 participants · NA

    A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans

  • NCT04867954 · 146 participants

    Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

  • NCT05051618 · 146 participants · NA

    Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02918929, the US trial registry maintained by the National Library of Medicine. NCT02918929 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.